OncoMatch/Clinical Trials/NCT06589089
Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
Is NCT06589089 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies autologous hematopoietic stem cell for diffuse large b cell lymphoma.
Treatment: autologous hematopoietic stem cell — This is a prospective, single-arm, open study to observe the efficacy and safety of the CART-SCB regimen (Clinical Regimen for the Prospective Study of Autologous Hematopoietic Stem Cell Boost for the Improvement of Bone Marrow Suppression in Patients with High-Risk Immunohematologic Toxicity Lymphoma After Chimeric Antigen Receptor T (CAR-T)-Cell Immunotherapy Therapy) . After the patient has completed CAR-T therapy, if the patient has unrelieved hematologic toxicity, consider infusing a reserve of stem cells; if myelosuppression has not been significantly relieved, stem cell infusion can be performed again.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Prior therapy
Must have received: CAR-T cell therapy
Prior CAR-T cell immunotherapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
History of allogeneic hematopoietic stem cell transplantation
Lab requirements
Blood counts
Myelosuppression as determined by the investigator has occurred after CAR-T therapy
Cardiac function
Severe cardiovascular disease: grade II or greater myocardial ischemia or myocardial infarction, poorly controlled arrhythmias; grade III-IV cardiac insufficiency according to NYHA criteria, or cardiac ultrasound suggestive of a left ventricular ejection fraction (LVEF) <50%
Adequate organ function; Myelosuppression as determined by the investigator has occurred after CAR-T therapy; Suffering from severe cardiovascular disease: grade II or greater myocardial ischemia or myocardial infarction, poorly controlled arrhythmias; grade III-IV cardiac insufficiency according to New York Heart Association (NYHA) criteria, or cardiac ultrasound suggestive of a left ventricular ejection fraction (LVEF) <50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06589089 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic stem cell transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify